Your session is about to expire
← Back to Search
Monoclonal Antibodies
Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
Phase 2 & 3
Waitlist Available
Research Sponsored by CytoDyn, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing if a single drug, PRO 140, can keep HIV under control in patients who are stable on their current multi-drug treatment. The drug works by blocking the virus from entering cells. The goal is to see if patients can maintain their health with this simpler treatment.
Eligible Conditions
- HIV/AIDS
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: PRO 140 SC 700 mg weekly injections (Group C)Experimental Treatment1 Intervention
PRO 140 700 mg (175 mg/mL) SC injections per week
Group II: PRO 140 SC 525 mg weekly injections (Group B)Experimental Treatment1 Intervention
PRO 140 525 mg (175 mg/mL) SC injections per week
Group III: PRO 140 SC 350 mg weekly injection (Group A)Experimental Treatment1 Intervention
PRO 140 350 mg (175 mg/mL) SC injections per week
Find a Location
Who is running the clinical trial?
CytoDyn, Inc.Lead Sponsor
24 Previous Clinical Trials
2,062 Total Patients Enrolled